Sign in to continue:

Friday, February 27th, 2026
Market UpdatesSingapore SGX stocks

Venture Corporation (VMS SP) 2026 Outlook: Back to Growth, Stable Margins & Higher Dividends – Maybank Research Summary

Posted on February 27, 2026 at 10:27 am (GMT+8)

77
Views
Share on Facebook
Share on Twitter


Broker: Maybank Research Pte Ltd
Date of Report: February 27, 2026

Excerpt from Maybank Research Pte Ltd report.


Report Summary

  • Venture Corporation (VMS SP) is returning to growth after a challenging period, with net profit expected to recover starting FY26 and margins remaining strong due to good cost control and execution.
  • The company is actively expanding in data centre and lifestyle segments, rewarding shareholders with higher dividends and share buybacks, while maintaining a solid ESG framework and strong balance sheet with net cash and industry-leading profitability.

Above is an excerpt from a report by Maybank Research Pte Ltd. Clients of Maybank Research Pte Ltd can be the first to access the full report from the Maybank Research website: https://www.maybank-keresearch.com

Related Posts

Three-A Resources (TARE MK)
Minichart
September 23, 2024

Three-A Resources (TARE MK) Technical Overview and Stock Performance: Last Price: RM0.925 Target Price: RM0.995, RM1.04 Support Level: RM0.885 Stop-loss Level: RM0.88 Three-A Resources is also demonstrating positive technical momentum. The stock successfully closed...

Bursa KLSE stocksMarket Updates

Telekom Malaysia (TM) 2025 Outlook: Growth Prospects, Data Centre Expansion & Strategic Advantages Explained
minichart
July 16, 2025

Phillip Research Sdn Bhd (Malaysia) Report Date: 16 July 2025 Telekom Malaysia: Unlocking Long-Term Growth Amid Digital Convergence and Data Center Expansion Executive Summary: A Forward-Looking Telecom Giant Telekom Malaysia (TM), Malaysia’s leading integrated...

IPOMarket UpdatesSingapore SGX stocksstock of the day

China Medical System Targets Secondary Listing on SGX to Expand Southeast Asia Reach
minichart
June 29, 2025

Hong Kong-listed pharmaceutical group China Medical System (CMS) has filed for a secondary listing on the Singapore Exchange (SGX) mainboard, with trading expected to commence in July 2025. The move is part of CMS’s...

   Ad